Transient acantholytic dermatosis in a patient with prostate cancer by Khan, MS et al.
UC Davis
Dermatology Online Journal
Title
Transient acantholytic dermatosis in a patient with prostate cancer
Permalink
https://escholarship.org/uc/item/02s0n1zr
Journal
Dermatology Online Journal, 26(2)
Authors
Khan, MS
Khan, M
Aivaz, O
Publication Date
2020
License
https://creativecommons.org/licenses/by-nc-nd/4.0/ 4.0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Volume 26 Number 2| February 2020| 
26(2):6 
 
 
- 1 - 
Dermatology Online Journal  ||  Case Presentation 
Transient acantholytic dermatosis in a patient with prostate 
cancer 
MS Khan1 DO, M Khan2 MD, O Aivaz3 MD 
Affiliations: 1Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA, 
2Foundation University Medical College, Islamabad, Pakistan, 3Department of Dermatology, Cedars-Sinai Medical Center, Los 
Angeles, California, USA 
Corresponding Author: Mohammad S. Khan, DO, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, Tel: 
407-879-2764, Email: mohammad.khan@cshs.org 
 
 
 
 
Keywords: Transient-acantholytic dermatosis, TAD, 
immune-related adverse events, irAEs 
 
Introduction 
Transient-acantholytic dermatosis also known as 
transient acantholytic dermatosis occurs generally 
among Caucasian males (male-to-female ratio 2.4:1 
with a mean age at diagnosis of 61 years) with an 
incidence of 0.8%. It presents clinically as a 
papulovesicular eruption on the trunk and proximal 
extremities [1]. Histologically, the disease manifests 
as small well-circumscribed foci of supra-basal 
acantholysis with dyskeratosis, a spongiotic 
epidermis, lymphohistiocytic interface dermatitis, 
and peri-vascular infiltrates [2]. The rash can be 
exacerbated by exercise, heat, sweat, ultra-violet 
light, friction, and malignancy. 
Particularly in cancer patients, TAD has been 
reported to occur in four different settings: (1) 
idiopathic, (2) after antineoplastic therapy, (3) after 
radiation therapy, and (4) paraneoplastic. Peculiarly, 
as part of a paraneoplastic syndrome, the 
appearance of TAD has led to the detection of a co-
existing malignancy or the resolution of TAD has 
coincided with a favorable response to therapy for 
that malignancy [3]. Predominantly hematological 
malignancies have been associated with TAD, 
occurring in 8% of cases [4]; reports of somatic 
malignancies associated with TAD are fewer in 
number (see Box 1). 
On the other hand, in this era of an ever-expanding 
list of drugs used to treat advanced cancer, it is no 
Abstract 
Transient acantholytic dermatosis (TAD) is a relatively 
common entity that has been also noted to occur in 
patients with cancer. Herein, we describe a case of 
transient acantholytic dermatosis occurring in a 
patient with a history of prostate cancer status post 
radiation, now being treated with combination 
therapy with pembrolizumab and carboplatin-
pemetrexed for advanced lung adenocarcinoma. Our 
case emphasizes the importance of being cognizant 
of TAD and its associations, particularly in cancer 
patients.  
 
Figure 1. Dermatologic findings after the first course of 
pembrolizumab treatment. A) Clinical presentation. Overview 
image showing diffuse eruption of a papulovesicular rash on the 
patient's upper trunk. 
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surprise that the list of drugs associated with TAD 
also keeps growing. Drug-induced triggers known to 
precipitate TAD include interleukin-4 [5], D-
penicillamine [5, 6], ribavirin [6], anastrozole [7], and 
anti-neoplastic drugs, including immunotherapy [2, 
8-11], among many others (see Box 2). TAD has also 
been associated with 2-chlordeoxyadenosine in 
patients being treated for hairy cell leukemia [3]. 
Given the multifactorial etiology of TAD, it is then 
important to be cognizant and familiar with this 
entity and its associations, particularly in managing 
cancer patients. 
 
Case Synopsis 
We report a case of a 78-year-old man with a history 
of prostate cancer, status post radiation therapy and 
currently being treated with pembrolizumab and 
carboplatin-pemetrexed combination therapy for 
stage IV lung adenocarcinoma of the left lower lobe. 
The tumor cells were positive for PDL-1 with 40% 
expression analyzed via immunohistochemistry. 
Pertinent laboratory values were unremarkable with 
peripheral eosinophil counts being normal. 
Shortly after initiation of the second cycle of 
combination therapy, the patient developed a 
generalized rash. Physical examination revealed a 
widespread painless polymorphic papulo-vesicular 
dermatosis on photo-distributed areas to include the 
upper back, chest, and upper extremities with 
intense pruritus and mild exfoliation; there was no 
notable improvement with oral benadryl and topical 
hydrocortisone (Figure 1). The patient reported no 
history of prolonged sun exposure, fever, infection, 
abundant sweating, autoimmune disease or a 
previous episode of TAD-like eruption. Skin biopsy of 
the lesions on the mid chest revealed focal vacuolar 
alteration of the dermal/epidermal junction with 
necrotic keratinocytes, lymphocytes, and rare 
eosinophils in the dermis (Figure 2). The epidermis 
also demonstrated multiple foci of superficial 
acantholytic dyskeratosis accompanied by 
keratinocyte dysmaturation and parakeratosis. 
In this clinical context, the differential diagnosis was 
TAD versus drug eruption, including drug-induced 
TAD. The lesions were relatively asymptomatic and 
stable and treatment with combination therapy was 
continued owing to the mild severity of the rash. The 
patient was prescribed 0.1% topical triamcinolone 
cream to relieve pruritus and advised to avoid sun 
exposure. A close follow-up assessment eight days 
after initial presentation revealed that the rash was 
responsive to topical coritcosteroids with complete 
resolution. No other therapy related adverse events 
were noted in the patient at that time. 
Long term follow-up revealed that the patient had 
completed four cycles of combination therapy  
Box 2. Drugs associated with transient-acantholytic dermatosis. 
Anastrozole [7]  
Penicillamine [5,6]  
CTLA-4 inhibitors (ipilimumab) [2, 10-11]  
PD-1/PDL-1 inhibitors (pembrolizumab) [8-9]  
Ribavirin [6]  
2-chlorodeoxyadenosine [4,36]  
BRAF inhibitors (vemurafenib and dabrafenib) [37]    
Box 1. Malignancies associated with transient-acantholytic dermatosis. 
Hematopoietic malignancies:  
Acute myeloid leukemia [25-27] 
Non-Hodgkin’s lymphoma [28]  
Waldenstrom’s Macroglobulinemia (ie. lymphoplasmacytic lymphoma) [29]   
Angioimmunoblastic lymphadenopathy with dysproteinemia-like T-cell lymphoma [30]  
Myeloid sarcoma/ leukemia cutis [27,31]  
 
Solid malignancies: 
Carcinoma of the GU organs (prostate, urothelial, renal) [25,32]  
Laryngeal carcinoma [33]  
Melanoma [34]   
Non-small cell lung cancer [35]  
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followed by maintenance pembrolizumab with an 
initial partial response followed by recent disease 
progression demonstrated by CT scans. No 
recurrence of a rash or a dermatologic immune-
related adverse event (irAE) have been reported 
since the initial skin biopsy in 2017. Given that the 
patient was not a good candidate for aggressive 
cytotoxic therapy and recent disease progression, 
hospice care was recommended owing to failure to 
thrive. 
 
Case Discussion 
Given that our patient had multiple cancers and was 
currently receiving anti-neoplastic therapy, the 
possibility of drug-induced TAD was clinically raised 
because a wide range of irAEs have been associated 
with both anti-CTLA-4 and anti-PD-1/PDL-1 
inhibitors [8, 12-24]. In particular, TAD-like irAEs have 
been previously reported in patients treated with 
both ipilimumab [2, 10-11] and PD-1/PDL-1 
inhibitors [8, 9], but are rare events. In our case 
however, the fact that the patient’s rash resolved 
despite continuation of combination therapy and 
the patient did not develop a TAD-like rash despite 
subsequent cycles of combination therapy followed 
by maintenance pembrolizumab favors that the 
eruption was not drug induced. Given that TAD is a 
known association in multiple different settings in 
cancer patients, this finding is not surprising, but 
invariably helpful for patient management.  
 
Conclusion 
Our case demonstrates that it is important to be 
aware of TAD and its association within a variety of 
cancer settings, particularly with the ever-expanding 
list of therapies being used to treat advanced 
cancers. More importantly, the need for active 
dermatological surveillance and close follow-up has 
become ever more important in such patients, often 
requiring clinicopathological correlation to 
ultimately dictate clinical management. 
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